Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is expected to continue its positive trend as a biopharmaceutical company developing novel oral small-molecule therapeutics targeting chronic diseases with unmet medical needs through its differentiated technology platform and expertise in computational chemistry. The recent success of their aleniglipron program validates their oral small molecule platform and GPCR targeting capabilities, increasing confidence in their ability to execute on next-generation assets. Investor interest and potential partnerships for their amylin program also provide additional upside potential for the company.

Bears say

Structure Therapeutics is emerging as a key player in the biopharmaceutical industry thanks to their innovative technology platform and focus on G-protein coupled receptor (GPCR) therapeutics. However, despite positive breakthrough data for their lead drug, aleniglipron, there are concerns about the drug's tolerability profile and potential competition from other drugs in the incretin family. This, along with a recently announced equity financing, raises questions about the company's financial stability and potential for upside in the near future.

GPCR has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 11 analysts, GPCR has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.